DUBLIN--(http://www.researchandmarkets.com/research/f7klvf/hospitaltreated) has announced the addition of Decision Resources, Inc's new report "Hospital-Treated Infections (Event Driven)" to their offering.)--Research and Markets (
Hospital-treated infections (HTIs) continue to represent a high-value segment of the overall antibacterial market owing to their severity and relatively high incidence. With numerous antibiotics spanning a diverse set of classes, the HTI therapy market is currently well-served and is expected to become crowded with generics as blockbuster antibiotics face patent expiry.
Developers of new antibiotics seeking commercial success in the HTI market will face stiff competition from established therapies, heightened regulatory scrutiny, and more-stringent reimbursement policies. Despite these challenges, unmet needs in certain segments (e.g., gram-negative infections) represent untapped market opportunity for novel therapies that offer improvements overand are sufficiently differentiated fromcurrent products.
An expanding population of at-risk patients and the growing prevalence of antibiotic-resistant pathogens will also fuel the need for novel antibiotics in the coming decade.
Key Topics Covered:
1 . Etiology and Pathophysiology
2 . Epidemiology and Patient Populations
3 . Current Therapies and Medical Practice
4 . Unmet Needs
5 . Emerging Therapies
6 . Market Outlook
For more information visit http://www.researchandmarkets.com/research/f7klvf/hospitaltreated
Source: Decision Resources, Inc